Exceptional response to trastuzumab deruxtecan in recurrent neuroendocrine cervical cancer: A case report
Objective: Neuroendocrine cervical carcinomas (NECC) are a rare and aggressive cervical cancer subtype that account for 1–1.5 % of all cervical cancers. Treatment options for recurrent NECC are limited and anticipated response rates are low. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Gynecologic Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578925001237 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|